n. • Other therapies in development: Despite the high unmet need for the treatment of RSV, there is a dearth of emerging treatments in the clinic. Alnylam and Cubist were collaborating on ALN-RSV, but further development has slowed since Cubist opted-out of the collaboration after a mixed result in a

t improve effectiveness of delivery. While it minimizes immunotoxicity and other undesired side effects. The Company has licenced its technology to Alnylam and Merk&Co with the former providing royalty bearing access to some of its partners. TKMR has an ongoing research relationship with Bristol-Myers S